Nanopharmacy professor Scott McNeil calls for uniform approval procedures for nanomedicines such as Covid-19 vaccines. (Photo: University of Basel, Andreas Zimmermann)
Nanopharmacy professor Scott McNeil calls for uniform approval procedures for nanomedicines such as Covid-19 vaccines. (Photo: University of Basel, Andreas Zimmermann) Nanomedicine involves packaging drugs in microscopic particles to make them more effective. Nanopharmacy professor Scott McNeil explains the opportunities presented by the new technology and what is still holding it back: approval procedures, for example, as seen in the inconsistent approach taken with the Covid-19 vaccines. Professor McNeil, your research group focuses on nanomedicine and the development of nanopharmaceuticals. What exactly does that mean? Put simply, it has to do with drugs that consist of particles that are between one and one hundred nanometers in size. A nanometer is approximately 30,000 times thinner than a human hair. One current example is the new Covid-19 vaccines Spikevax and Comirnaty, in which the mRNA is packaged in microscopic lipid nanoparticles.
TO READ THIS ARTICLE, CREATE YOUR ACCOUNT
And extend your reading, free of charge and with no commitment.
